Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Decreased circulating complement factor H concentration, Depletion of components of the alternative complement pathway, Blood in the urine (hematuria), and Recurrent bacterial infections and 3 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 4 | Blood in the urine (hematuria), Glomerular subendothelial electron-dense deposits, Chronic kidney disease |
CFH encodes complement factor H (1,231 aa). Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Highest expression in Artery Coronary (362.4 TPM) and Liver (332.3 TPM).
Complement factor H deficiency is associated with mutations in the CFH gene on chromosome 1.
CFH is classified as a druggable target (Druggable Genome category) with score 26.1.
C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface); it is rarely inherited in a simple mendelian fashion.
C3G should be suspected in individuals of all ages who present with one of the following:
Hematuria
No approved treatments are currently available for complement factor H deficiency. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with C3G, the following evaluations are recommended if they have not already been completed:
Evaluate the complement system by measuring serum/plasma concentrations of C3, C3c, C3d, C4, C5, fB, Ba, Bb, fH, fI, properdin, and s(C5b-9).
The following are appropriate:
Close monitoring of renal function by a nephrologist with familiarity with the C3G disease spectrum
Note: Frequency of follow up and testing required is determined by the degree of renal dysfunction.
No clinical trials have been registered for complement factor H deficiency.
6 publications have been identified in PubMed for complement factor H deficiency. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Li X (2026). [PMID: 42060028](https://pubmed.ncbi.nlm.nih.gov/42060028/). *Mol Biomed*. [Basic Science / Preclinical]
Ma D (2025). [PMID: 39740399](https://pubmed.ncbi.nlm.nih.gov/39740399/). *Biochem Biophys Res Commun*. [Basic Science / Preclinical]
Ratajczak MZ (2025). [PMID: 40269269](https://pubmed.ncbi.nlm.nih.gov/40269269/). *Leukemia*. [Review / Meta-Analysis]
Xie H (2025). [PMID: 40373713](https://pubmed.ncbi.nlm.nih.gov/40373713/). *Ecotoxicol Environ Saf*. [Basic Science / Preclinical]
Regnier M (2025). [PMID: 39422762](https://pubmed.ncbi.nlm.nih.gov/39422762/). *Pediatr Nephrol*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about complement factor H deficiency
Blood and immune system |
1 |
Recurrent bacterial infections |
Age of onset. C3 glomerulopathy (C3G) affects individuals of all ages. report a 1:1 female:male distribution and a median age at diagnosis of 23 years. In comparing the two major subtypes, the median age at time of diagnosis in C3 glomerulonephritis (C3GN) is higher than in dense deposit disease (DDD). In childhood, DDD is more frequently diagnosed than C3GN . Renal disease. Individuals with C3G typically present with one of the following findings:
Hematuria
Proteinuria
Hematuria and proteinuria
Acute nephritic syndrome
Nephrotic syndrome
Hypocomplementemia. Individuals with C3G have low levels of complement component C3. Complement dysregulation can be mediated by autoantibodies . Autoantibodies that may be detected in individuals with C3G:
Source: GeneReviews — "C3 Glomerulopathy"
To date, the most striking genotype-phenotype correlation has been with CFHR fusion genes and the C3GN phenotype (as opposed to the DDD phenotype) .
Source: GeneReviews — "C3 Glomerulopathy"
Hematuria and proteinuria
Acute nephritic syndrome
Nephrotic syndrome
Persistent hypocomplementemia (low serum levels of complement component C3)
The diagnosis of C3G is established in a proband with typical findings on renal biopsy. Some individuals will have biallelic or heterozygous pathogenic variants identified by molecular genetic testing in one or more of the genes listed in...
Source: GeneReviews — "C3 Glomerulopathy"
Table 3. Disorders to Consider in the Differential Diagnosis of C3G
Disorder | Gene(s) | MOI | Clinical Features of This Disorder |
|---|---|---|---|
Overlapping w/C3G | Distinguishing from C3G Post-infectious glomerulonephritis1 | NA | Acquired |
Immune-complex MPGN2 | NA | Acquired | Hematuria, proteinuria, C3 deposits, subendothelial subepithelial deposits, progressive disease |
Juvenile acute non-proliferative glomerulonephritis3 | NA | Acquired | Mesangial cell proliferation, subepithelial deposits on EM |
LCAT | AR | ESRD, glomerular pattern of IF similar to dense deposit disease | Abnl lipoprotein (lipoprotein X); corneal opacities; normochromic anemia; capillary endothelial damage; cross-striated vacuole structures |
Partial lipodystrophy5 | Several genes | AD/AR | Loss of subcutaneous fat in upper half of the body |
Age-related macular degeneration6 | Many genes | AD | Drusen |
EFEMP1 | AD | Drusen | No renal disease abnl = abnormal; AD = autosomal dominant; AR = autosomal recessive; EM = electron microscopy; IF = immunofluorescence; MOI = mode of inheritance; MPGN = membranoproliferative glomerulonephritis; nl = normal 1. , , , 2. , , 3. , 4. , 5. , , , , 6. , , , 7. , , , , |
Source: GeneReviews — "C3 Glomerulopathy"
Genetic testing for CFH is available. Testing is considered confirmatory for diagnosis.
Quantitate the degree of complement function by measuring CH50 and APH50.
Measure autoantibodies including C3NeFs, C4NeFs, C5NeFs, FHAA, and FBAA.
Establish the extent of renal disease by measuring serum creatinine concentration, and monitor creatinine clearance, proteinuria, and hematuria.
Quantitate the degree of chronic renal damage by renal biopsy.
Obtain a baseline ophthalmologic examination.
Consult with a clinical geneticist and/or genetic counselor.
Currently, there are no therapeutic agents specifically designed to target the underlying complement dysregulation that occurs in individuals with C3G. Nonspecific therapies are most commonly used. Nonspecific therapies have been shown to be effective in numerous chronic glomerular diseases. The judicious use of these agents along with optimal blood pressure control is of benefit in individuals with C3G.
Source: GeneReviews — "C3 Glomerulopathy"
Numerous anti-complement therapies are entering clinical trials for individuals with C3G. These trials are registered under ClinicalTrials.gov. Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "C3 Glomerulopathy"
View trials for complement factor H deficiency
Periodic eye examinations to evaluate the fundus
Source: GeneReviews — "C3 Glomerulopathy"